MedWatch

Tough competition forces innovation at Ambu

Ambu is intensifying its efforts to create the next generation of its duodenoscopes. A number of competitors are circling, and an upcoming tender is a good opportunity for income. CEO Juan Jose Gonzalez calls the new duodenoscope the biggest earner of the future.

Juan Jose Gonzalez, CEO of Ambu | Photo: Ambu/PR

As CEO of Ambu, Juan Jose Gonzalez has looked forward to announcements of tenders for single-use endoscopes in the US. However, competitors are homing in on Ambu's key business area.

The CEO expects duodendoscopes to be the biggest market within single-use endoscopes in 2024-2025, so although the company only recently launched its current product in the US, Gonzalez is already throwing his weight behind the development and launch of the next generation, while competitors circle ahead.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs